[Establishment of a living biobank : Improved guidance of precision cancer care with in vitro and in vivo cancer models].

Pauli, C; Moch, H; Rubin, Mark Andrew (2017). [Establishment of a living biobank : Improved guidance of precision cancer care with in vitro and in vivo cancer models]. Der Pathologe, 38(Suppl 2), pp. 160-168. Springer 10.1007/s00292-017-0346-1

[img] Text
10.1007%2Fs00292-017-0346-1.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (5MB) | Request a copy

BACKGROUND Precision oncology is a clinical approach aimed towards tailoring treatment strategies for patients based on the genetic profile of each patient's cancer. The integration of a living biobank, consisting of patient-derived tumor organoids and PDXs, with next generation sequencing approaches and high-throughput drug screening help to guide clinical decision-making and clinical trial development. METHODS Tumor organoids derived from fresh tumor samples were used for in vitro and in vivo high-throughput drug testing. RESULTS Over a period of two years we established 56 in vitro tumor organoids and 19 in vivo xenografts from 18 different solid tumor types. Tumor morphology and molecular profiles show good concordance between the in vitro and in vivo models compared to their native tumor. High-throughput drug screening (up to 160 drugs) has been tested on eight tumor organoid lines. Seven of them underwent an additional combination drug screen. We nominated several targeted small molecules and novel combinations that have been validated in corresponding xenograft models. CONCLUSION This precision medicine approach outlines the integration of genomic data with drug screening from personalized preclinical cancer models to guide precision cancer care. It also fuels next generation research and has been implemented for clinical trial development.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Präzisionsonkologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Präzisionsonkologie

UniBE Contributor:

Rubin, Mark Andrew

Subjects:

500 Science
500 Science > 570 Life sciences; biology

ISSN:

1432-1963

Publisher:

Springer

Language:

German

Submitter:

Marla Rittiner

Date Deposited:

12 Feb 2018 09:57

Last Modified:

22 Oct 2019 18:59

Publisher DOI:

10.1007/s00292-017-0346-1

PubMed ID:

28956107

Uncontrolled Keywords:

Clinical decision-making Drug evaluation Precision medicine Tumor Organoids Xenografts

BORIS DOI:

10.7892/boris.110750

URI:

https://boris.unibe.ch/id/eprint/110750

Actions (login required)

Edit item Edit item
Provide Feedback